Literature DB >> 22812189

PIK3CA is critical for the proliferation, invasiveness, and drug resistance of human tongue carcinoma cells.

Yu Chen1, Qingyi Hou, Wangxiang Yan, Jing Luo, Dan Chen, Zhiguo Liu, Shuqi He, XueQiang Ding.   

Abstract

PIK3CA is an oncogene component of phosphatidylinositol 3-kinase (PI3K) signaling pathway and is associated with cell proliferation and carcinogenesis in a variety of human cancers. PIK3CA mutation is correlated with the aggressiveness of many epithelial cancers. And so PIK3CA is considered as a major oncogene in many human epithelial malignancies. However, its role in tongue carcinoma is unknown. We used lentiviral-mediated interfering short hairpin RNAs (shRNAs) to knock down PIK3CA expression in tongue carcinoma Tca8113 cells, and then we tested the cell proliferation by MTT assay and cell invasiveness by cell invasion assay. To examine whether PIK3CA is involved in the response of Tca8113 cells to an anticancer drug, cisplatin, we further performed cell death analysis by fluorescence-activated cell sorting (FACS). We found that knocking down PIK3CA led to slower cell growth and lessened cell invasiveness. In addition, PIK3CA downregulation increased Tca8113 cell death after cisplatin treatment, suggesting that PIK3CA downregulation might be helpful to increase the effects of some anticancer drugs. Moreover, in a mouse model of established large sized OSCC, we showed that suppression of PIK3CA markedly diminished tumorigenicity in vivo. To understand its molecular mechanism of action, we measured expression of phospho-PTEN (Ser380) and phospho-AKT (Ser473) by Western blot and found that suppression of PIK3CA inhibited OSCC growth through downregulation of p-PTEN and p-AKT. Our study highlights critical roles for PIK3CA in the tongue cancer, and suggests that PIK3CA gene might be considered as a therapeutic target for clinical tongue cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22812189     DOI: 10.3727/096504012x13340632812677

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  3 in total

1.  Evaluation of AKT phosphorylation and PTEN loss and their correlation with the resistance of rituximab in DLBCL.

Authors:  Yihui Ma; Pengyu Zhang; Yi Gao; Huijie Fan; Mingzhi Zhang; Jingjing Wu
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

2.  Clinicopathological Significance of Elevated PIK3CA Expression in Gastric Cancer.

Authors:  Si-Hyong Jang; Kyung-Ju Kim; Mee-Hye Oh; Ji-Hye Lee; Hyun Ju Lee; Hyun Deuk Cho; Sun Wook Han; Myoung Won Son; Moon Soo Lee
Journal:  J Gastric Cancer       Date:  2016-06-24       Impact factor: 3.720

Review 3.  Immunosuppressive Signaling Pathways as Targeted Cancer Therapies.

Authors:  Botle Precious Setlai; Rodney Hull; Meshack Bida; Chrisna Durandt; Thanyani Victor Mulaudzi; Aristotelis Chatziioannou; Zodwa Dlamini
Journal:  Biomedicines       Date:  2022-03-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.